We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 29% above its sector, the market expects faster growth.
Globally, Bora Pharmaceuticals Co., LTD. is engaged in the comprehensive lifecycle of pharmaceutical products, encompassing research and development, manufacturing, distribution, and sales. The organization operates through key divisions, including Sales, Contract Development & Manufacturing Organization (CDMO), and other ancillary services. Bora produces and markets a diverse range of medicines, from generic and proprietary brand-name drugs to over-the-counter (OTC) remedies. Beyond its in-house portfolio, the company provides extensive contract development and manufacturing solutions. These CDMO services cover all stages of pharmaceutical development, clinical and commercial production, specialized packaging and serialization, rigorous analytical and microbiological quality control, and expert guidance on regulatory compliance. Furthermore, Bora's offerings extend to nutritional supplements, skincare products, and various biotechnical services. The company distributes its goods directly to healthcare facilities such as clinics, pharmacies, and pharmacy chains, as well as to drugstores. It also leverages distributors to supply larger institutions like medical centers, corporate and public hospitals, and regional and district hospitals. Established in 2007, Bora Pharmaceuticals Co., LTD. is based in Taipei City, Taiwan.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 6472.TW and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
